Neuroendocrine Tumor Treatment Market Size & Share, by End-user (Hospitals, Clinics); Therapy (Somatostatin Analogs, Chemotherapy, Cancer Immunotherapy, Targeted Therapy); Indication (Lungs, Pancreas, Gastrointestinal) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3846
  • Published Date: Aug 08, 2023
  • Report Format: PDF, PPT

Companies Dominating the Neuroendocrine Tumor Treatment Market

top-features-companies
    • BoehringerIngelheim International GmbH
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Hutchison MediPharma Limited,
    • AVEO Oncology
    • Pfizer, Inc.
    • IpsenPharma
    • Tarveda Therapeutics
    • Progenics Pharmaceuticals
    • Novartis AG
    • Eli Lilly & Company
    • Ipsen Pharma

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Eli Lilly & Company to supply its human insulin active pharmaceutical ingredient (API) to IABL at a reduced cost in order to facilitate the manufacturing of insulin in Bangladesh.
  • Boehringer Ingelheim teamed up with 3T Biosciences to identify and create cutting-edge cancer treatments to meet the significant unmet patient needs. Further, the collaboration will combine the industry-leading 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform from 3T Biosciences with Boehringer Ingelheim's two-pronged research approach combining cancer cell-directed and immune cell-targeting compounds.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3846
  • Published Date: Aug 08, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidence of neuroendocrine cancer is the major factor driving the market growth.

The market size of neuroendocrine tumor treatment is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 – 2035.

The major players in the market are BoehringerIngelheim International GmbH, Hutchison MediPharma Limited, AVEO Oncology, Pfizer, Inc., IpsenPharma, Tarveda Therapeutics, Progenics Pharmaceuticals, Novartis AG, Eli Lilly & Company, Ipsen Pharma, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying